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Summary A long term follow-up study has been undertaken in 33 patients with acute non-lymphoblastic
leukaemia (ANLL) in order to establish whether a correlation exists between the clinical course and the
immunologic pattern of lymphoid subpopulations. Peripheral blood lymphoid cells have been investigated
longitudinally (each 1 to 4 months) during complete remission (CR), by morphologic, phenotypic and
functional analyses. Particular attention has been paid to the evaluation of the natural killer (NK) cell
compartment, by the detection of cells expressing an NK-related phenotype and by NK in vitro assay. Among
the patients so far evaluable, 20 relapsed (R) and 10 are long survivors in CR 'off therapy' (LS). The most
relevant finding was represented by statistically higher values of NK activity observed in LS vs. R patients
(P<0.01). The removal of adherent cells before the NK assay, performed to investigate the possible inhibitory
effect on NK function played by the macrophage component, abolished this difference, due to a selective
increase of NK function in the R group. The longitudinal study revealed that NK activity tended to decrease
in individual patients who subsequently relapsed. These data suggest a possible role of NK cells in the relapse
control of ANLL, although it cannot be excluded that the low level of NK activity observed in the R group is
the result of impending relapse rather than its cause.
Recent advances in the treatment of acute non-lymphoblastic
leukaemia (ANLL) led to a substantial increase in the
number of patients who experience prolonged complete
remissions (CR) which may-end in a cure of the disease in a
proportion of cases (Champlin et al., 1985). The best results
seem to be obtained in patients submitted to allogeneic bone
marrow transplantation (BMT) (Dinsmore et al., 1984; Gale
& Champlin, 1986). Unfortunately, less than 10% of ANLL
patients can take advantage of this procedure for a number
of reasons, including the lack of compatible donors, age over
40, and complications related to the transplant (Gale &
Champlin, 1986). Despite therapeutic improvements, the
overall results seem to indicate that a relapse still occurs
within 18 months from the achievement of CR in the
majority of patients with ANLL (Champlin et al., 1985; Rees
et al., 1986). A number of prognostic factors, possibly
independent of treatment, have been suggested to be asso-
ciated with the duration of CR (reviewed by Gale & Foon,
1986). Some of them are likely to be related to intrinsic
biological properties of the leukaemic cells, such as cellular
lineage, kinetic parameters, chromosome abnormalities, enzy-
matic pattern, etc. Other prognostic factors seem to be more
connected with the host, including sex, age, and immuno-
logic reactivity. In particular, the last of these could play a
role in controlling the proliferation of the residual leukaemic
cells eluding the treatment and eventually responsible for the
relapse. Beside some experimental evidence (Cheever et al.,
1980; Karre et al., 1980), the possibility of such an immuno-
logic control mechanism is also supported by a number of
clinical reports. Among them, the beneficial effect of viral
hepatitis in ANLL (Barton & Conrad, 1979; Rotoli et al.,
1982), and the apparent anti-leukaemia effect of graft-versus-
host-disease (GvHD) following allogeneic BMT (Weiden et
al., 1979; Bacigalupo et al., 1985). Both these conditions are
characterised by major alterations of the phenotypic and
functional profiles of the reactive lymphoid cells, including
those accounting for cytotoxic mechanisms (Chemello et al.,
1986; Dienstag & Bhan, 1980; Lopez et al., 1979).
In this paper we investigated the correlations between the
clinical course of ANLL and the immunologic pattern of
their lymphoid subpopulations, in order to look for indirect
evidence of a possible mechanism which might be involved in
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the control of relapse. For this purpose, peripheral blood
mononuclear cells (PBMC) of 33 patients with ANLL in
their first CR were longitudinally evaluated by morphologic,
phenotypic, and functional approaches. Particular attention
was paid to the analysis of the natural killer (NK) cell
compartment, since it is believed to represent the first-line of
defence against the spread of tumour cells (Herberman,
1983).
Patients and methods
Patients
Thirty-three patients (15 males, 18 females; mean age 37,
range 14-67 years) were studied, from March 1983 to June
1987, during their first CR. All of them had a diagnosis of
ANLL made in our institution between January 1978 and
December 1986 on the basis of standard criteria, according
to the French-American-British (FAB) classification system
(Bennett et al., 1976). All patients received a similar treat-
ment based on a standard induction therapy with 3 to 4
courses of adriamycin, thioguanine and cytosine arabinoside,
and on a maintenance therapy with COAP regimen (White-
car et al., 1972) alternated with cytosine arabinoside and
thioguanine (100mgm-2 each, twice a day for 5 days) given
monthly for 20-30 months after the achievement of CR, or
until relapse if it occurred earlier.
Eight out of 33 patients entered the study when they were
long survivors (CR>30 months) 'off therapy' from 3 to 40
months. Seven of them are still in their first CR (CR 65-118
months), and one relapsed. Twenty-five out of 33 patients
entered the study during the maintenance therapy, 2 to 20
months from the end of the induction treatment. Among
them, 3 are now 'off therapy' long survivors in CR (CR 40,
58, and 65 months), 3 are still on maintenance therapy in
CR, and 19 relapsed (CR 4-39 months).
Overall, 10 patients are at present long survivors 'off
therapy' in CR (LS group), 20 relapsed (R group), and 3 are
still on maintenance therapy not yet long survivors (CR<30
months). Data on these latter 3 patients have not been
considered in the analysis.
Clinico-haematological evaluation
Clinical reports of all patients were re-evaluated at the time
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of entry to the study. This was carried out longitudinally
during the CR by the concomitant evaluation, at 1 to 4
month intervals, of several clinico-haematological, pheno-
typic, and functional parameters. In patients on maintenance
therapy these multiparameter investigations were performed
after a minimum period of 30 days from the end of therapy.
The number of observations was 134 in LS and 113 in R,
ranging from 3 to 12 in the different patients. Seventy-nine
per cent of determinations were performed during mainten-
ance therapy in the R group, as opposed to 19% in LS. The
clinico-haematological evaluation included physical examin-
ation, complete blood counts and careful observation of
May-Grunwald-Giemsa stained PB smears.
Phenotypic analysis
Cell suspensions from PBMC were obtained by Ficoll-
Hypaque gradient separation from freshly drawn heparinised
blood and incubated with fluorochrome-conjugated mono-
clonal antibodies. These included OKT11 (CD2) (from
Ortho Pharmaceutical, Raritan, NJ), Leu3 (CD4), Leu2
(CD8), Leu7, and Leul 1 (CD16) (from Becton-Dickinson,
Sunnyvale, CA). OKT1I binds the sheep erythrocyte recep-
tor (Reinherz et al., 1980); Leu3 and Leu2 react with the two
lymphocyte subsets which include helper and cytotoxic/
suppressor cells, respectively (Reinherz et al., 1980); Leu7
and Leull react with antigens related to the NK compart-
ment (Lanier et al., 1983). The evaluation was made with a
fluorescence microscope on 300 cells per sample.
NK cell activity
NK activity was assessed by evaluating the lysis of 51Cr-
labelled K-562 target cells (Semenzato et al., 1986). Briefly,
I x 106 target cells were labelled overnight at 37°C in 5%
CO2 atmosphere with 100pCi Na2(5"Cr)O4 (CIA IRE Sorin,
Biomedica, Saluggia, Italy) and extensively washed before
use. Cells (1 x 104) were resuspended in each well of a V-
shaped plate (Titertech, Falcon Lab.) and graded concen-
trations of PBMC were added to wells in triplicate and
incubated for 4h at 37°C in 5% CO2. Following this
incubation, supernatants were harvested and counted in a
gamma counter. The mean value of triplicate assays was
used to calculate the percentage of cytotoxicity, as already
reported. The analysis of NK activity was performed com-
paring the values of cytotoxicity in the different groups at an
effector/target (E/T) ratio of 40:1. In 74% of determinations
NK activity was carried out simultaneously on unfraction-
ated PBMC and after removal of monocytes by adherence
to plastic dishes, as previously reported in detail (Semenzato
et al., 1986).
Statistical analysis
The number of determinations for each parameter was
variable from patient to patient, depending on the follow-up
period. Therefore, in order to avoid a disproportionate effect
of patients tested on a larger number of occasions, the mean
values were not calculated on the basis of each test result but
using one value per patient which represented the mean of
all figures observed in that patient. Results are expressed as
mean values+standard deviation (s.d.) and the comparison
between values has been performed using the Student's t-test
and analysis of variance (ANOVA).
Results
Clinico-haematological evaluation
The age and sex distribution was similar in the two groups.
The various morphological categories of the FAB classifica-
tion were nearly all represented in both groups, with a
higher concentration of M4 (myelo-monocytic type) in R (11
out of 20 cases) as compared to LS (2/10). The presence of
antibodies against virus hepatitis B (HBsAb+) was detected
in 7 out of 10 cases (70%) in LS, versus 3 out of 20 (15%) in
R. In most HBsAb+ cases, clinical and/or laboratory signs
of hepatitis had been observed during the induction treat-
ment or soon after the achievement of CR. Furthermore,
one patient belonging to the LS group had developed a non-
A, non-B viral hepatitis.
The absolute numbers (mean+s.d.) of lymphocytes, mono-
cytes, and large granular lymphocytes (LGL), as emerged
from all longitudinal determinations, are shown in Table I.
The mean values of lymphocytes were similar to age-
matched controls in both groups. The monocyte values were
similar in LS and R, but the figures were statistically
different from controls only in LS (LS<C; P<0.01). LGL
values were higher in LS as compared to R (P<0.05) and
controls (P<0.01).
Phenotypic analysis
Data are also shown in Table I. The mean values of T cells
(CD2+) in LS and R were similar to controls. The CD4/
CD8 ratio was lower than control values both in LS and R.
Leul1+ cells were higher in LS than in R (P<0.05). The
mean values of Leu7+ cells, although slightly higher in LS as
compared to R, were not statistically different in the two
groups.
NK cell activity
The overall results of NK activity detected on PBMC non-
monocyte-depleted at E/T ratio of 40:1 are reported in
Table II. The figures were higher in LS as compared to R
(P<0.01). However, the LS values were not statistically
different from controls. The analysis of individual values
indicates that determinations below the interval of normality
were 18% in LS as compared to 57% in R. On the other
hand, the determinations exceeding the control range were
31% in LS, and 5% in R. Monocyte depletion by the
removal of adherent cells reduced the differences in terms of
NK activity observed between LS and R on PBMC 'non-
depleted' (Table II). This was mainly due to an increase of
Table I Morphologic and phenotypic analyses of lymphoid cells in ANLL in CR. Mean values+s.d. of
longitudinal data in long survivors, patients who subsequently relapsed, and in controls.
Long survivors Relapsed Controls
Parameters (LS=J0) (R=20) (C=25) P value
Lymphocytesa 2.02+0.44 2.02+0.66 2.32+0.49 NS
LGLa 0.75+0.33 0.48+0.26 0.36 +0.17 LS-C<0.01
LS-R<0.05
Monocytesa 0.31 +0.08 0.34+0.15 0.42+0.11 LS-C<0.01
CD2+ (Tll +)a 1.35+0.34 1.33+0.49 1.67+0.27 R-C<0.01
Leu7+a 0.41 +0.22 0.32+0.18 0.44+0.24 NS
Leull +a 0.23+0.15 0.13+0.09 0.18+0.12 LS-R<0.05
CD4/CD8 1.62+0.73 1.51 +0.87 2.40+0.79 R-C<0.01
ax 1091-1; NS: not significant.
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Table 11 In vitro NK activity of PBMC (as expressed by percentage of 5"Cr release at effector target
ratio 40:1) in patients with ANLL in CR and controls (mean values+s.d.)
Percentage of 51Cr release
Patient groups PBMC non-depleted PBMC monocyte depleted P value
A B A vs. B
Long survivors (LS) 36.0+ 10.3 39.6+ 10.6 NS
Relapsed (R) 19.7+ 11.4 28.3+11.7 P<0.001
Controls (C) 32.3 + 11.0 34.2+13.4 NS
P value: LS vs. R:
LS vs. C:
R vs. C:
P<0.01
NS
P<0.02
NS
NS
NS
NK activity in R (from 19.7+ 11.4 to 28.3+ 11.7; P<0.001).
NK values before and after monocyte removal were not
statistically different in LS and C.
60
40 Phenotypic andfunctionalfluctuation during CR
In the majority of patients the various lymphoid sub-
populations, as defined by morphologic and phenotypic
parameters, did not show major fluctuations during the
observation period. However, in 12 out of 30 cases this was
found to occur for one or more of the considered para-
meters. Although in these patients it was difficult to establish
a definite trend, in 9 cases who subsequently relapsed a
decrease of Leu7, Leull, and CD4/CD8 ratio values could
be observed 2 to 4 months prior to the relapse.
The data on NK cell activity analysed in individual
patients showed a more composite pattern. In LS, 4 out of
10 patients had values consistently exceeding the range of
controls (Figure 1, representative case 1), 4 had the large
majority of their values within the normal range (Figure 1,
representative case 2) and 2 showed wide fluctuations with
several values below the normal range. Among the 20
patients of the R group, the values during the follow-up
period were mostly concentrated below or at the lower limit
of normality in 14 cases (Figure 1, representative case 4)
while they were variable and scattered in 6. In 10 cases of
this group (see Figure 1, representative case 3) the NK
values observed during the last 1-4 months of CR, just
before the relapse, dropped to lower levels as compared to
the mean values of previous determinations of each given
case. In these patients the reduction of 5"Cr release of pre-
relapse values was between 9 and 30% (mean 17%).
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Discussion
Our study indicates that long surviving patients with ANLL
in CR exhibit higher in vitro NK activity of PBMC,
associated with increased levels of NK-related cells (LGL
and Leu11+), as compared to patients who subsequently
relapsed. Other major phenotypic differences were not
observed between the two groups. These data suggest a
possible role of NK cells in the relapse control of ANLL.
However, this suggestion has to be considered with caution,
since the study is also open to other plausible interpre-
tations. First, the differences observed between the two
groups could be related to the effect of therapy. In fact, 79%
of determinations were performed during maintenance ther-
apy in the R group, as opposed to 19% in LS. Although it is
possible that therapy might have influenced some para-
meters, a number of considerations suggest that the differ-
ences observed in terms of NK function and/or inhibition of
NK activity by adherent cells, may not be merely attribut-
able to therapy. The therapy-related depression of NK
function previously reported in patients with acute leukaemia
(Fontana et al., 1984; McGeorge et al., 1982) was shown to
be confined to the period of treatment, with recovery of NK
activity within days after therapy ceased (McGeorge et al.,
1982). In all patients investigated during maintenance ther-
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Figure 1 In vitro longitudinal variations of NK activity of
PBMC in 4 representative cases of patients with ANLL investi-
gated during complete remission. Shaded area defines the range
(mean+s.d.) of controls. Months refer to the achievement of
complete remission. Arrows in cases 3 and 4 indicate the time of
relapse.
apy, immunological tests were performed just prior to initiat-
ing each subsequent course, at least one month after the
previous one. Other indirect suggestions against a major role
of therapy in modifying the results come from the analysis of
data in individual patients. In 3 cases who became long-term
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survivors during the study, the values of NK activity, before
and after the removal of adherent cells, did not show any
significant variation after stopping therapy, with NK activity
values at the upper limits of normality in most determi-
nations (see case 2, Figure 1). In addition, the decrease of
NK values observed during the last months of CR in 10 out
of 20 patients who subsequently relapsed occurred with no
variation of therapy (see Figure 1, representative cases 3 and
4). The above considerations taken together, suggest that a
possible influence of therapy on the NK system is unlikely to
represent the major cause of the difference we observed in
the patient groups.
Although it cannot be excluded on the basis of our data
that the low level of NK activity observed in the R group is
the result of relapse rather than its cause, the alternative and
more exciting possibility indirectly suggested by our findings
is that a causative relationship exists between NK cell
activity and control of relapse, the former being higher in
patients who experienced longest survivals. This would be in
line with the well known capability of NK cells to inhibit the
in vitro growth of fresh clonogenic leukaemic cells (Beran et
al., 1983; Lotzova, 1985). If this is the case, a number of
possible mechanisms could be considered, which in vivo may
play a role in the control of the relapse, through a positive
or negative balance of NK function. These mechanisms
could be related either to the host or to the residual
leukaemic cells. Viral hepatitis has been shown to be asso-
ciated with prolonged survivals in ANLL (Barton & Conrad,
1979; Rotoli et al., 1982). Such an anti-leukaemia effect
could be related to the enhanced cytotoxic capability, which
is present on PBMC in these conditions (Chemello et al.,
1986; Dienstag & Bhan, 1980). Interestingly, viral hepatitis
occurred in 8 out of 10 LS patients (type B 7 cases; non-A,
non-B 1 case), as opposed to 3 out of 20 cases observed in
R. Thus, the higher incidence of viral hepatitis which
occurred in LS group could be correlated with the higher
NK cell activity observed in these patients who experienced
the longest survival.
The observed inhibitory effect on NK cell function prefer-
entially exerted by adherent cells on patients in the R group,
might also be of relevance as a negative factor in control of
leukaemia. The explanation for the greater inhibitory capabi-
lity observed in R patients as compared to LS is not simply
attributable to a quantitative difference of the monocyte
number between the two groups (R vs. LS =NS). The
stronger inhibition in R patients could be related to intrinsic
functional aspects of their monocyte component, possibly
through a mechanism involving the production of prosta-
glandins which are capable of inhibiting NK function
(Brunda et al., 1980; Combe et al., 1984; Hall et al., 1983).
Since the R group includes a large proportion of cases (11
out of 20) with M4 morphology, it is tempting to speculate
on the possible role of the residual leukaemic component as
the effector of NK inhibition. This leukaemic component
could well be undetectable as a blast cell population, since
normal-looking mature cells can belong to the leukaemic
progeny (Fearon et al., 1986). A negative influence on
disease control via inhibition of the NK system mediated by
functionally active residual leukaemic cells belonging to the
monocyte lineage would represent an interesting, if hypo-
thetical, explanation of the well known high relapse rate in
acute monycytic leukaemia (Appelbaum et al., 1984).
In conclusion, our data seem to support the possibility
that NK cells play a role in the control of relapse in ANLL.
However, this suggestion needs to be supported by further
studies on patient cytotoxic activity against autologous active
phase and relapse leukemia cells.
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